<DOC>
	<DOC>NCT00107978</DOC>
	<brief_summary>Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.</brief_summary>
	<brief_title>Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillinresistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection: major abscess requiring surgical incision and drainage; infected burn (see exclusion criteria for important qualifications); deep/extensive cellulitis; infected ulcer (see exclusion criteria for important qualifications); wound infections Patients must be expected to require at least 7 days of intravenous antibiotic treatment. Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy Burns involving &gt; 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>cSSSI (complicated Skin and Skin Structure Infections)</keyword>
	<keyword>Staph (Staphylococcus)</keyword>
	<keyword>MRSA (Methicillin-resistant Staphylococcus Aureus)</keyword>
</DOC>